SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (683)4/18/1997 8:01:00 PM
From: Brad C. Dunlap   of 1762
 
Hi Miljenko, you and I have better things to do then post back and forth but I do have one last question in reference to your previous post. Where did you get your info on a 20% royalty from Genentech on C2B8. My understanding is the company has never disclsosed this figure other then Genentech gets more then half. When Shekhar Basu was at Punk Ziegle and Eric Hecht was at Morgan both analyst used in their models 30-40% of the profits. Also for your info Smithkline has initiated the second phase III with CE9.1 for RA with methotrexate as of March 97.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News